All In Biotech

Drug Trial Radar · NCT00083824

Estrogen, HDL, and Coronary Heart Disease in Women

Last checked: Nov 20, 2026Latest source record: Apr 21, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 309 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

309

Actual

Start

Mar 2004

Primary completion

Feb 2007

Study completion Feb 2007

Sponsor

Lead sponsor
Tufts UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Heart, Lung, and Blood Institute (NHLBI)
First posted
Jun 4, 2004

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Health services research
Who can join
Female only, from 55 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To clarify the effects of estrogen, with or without progestin, on high density lipoprotein (HDL) in postmenopausal women.

Conditions

  • Cardiovascular Diseases
  • Coronary Disease
  • Heart Diseases
  • Coronary Arteriosclerosis

Interventions

  • Estrogens, Conjugated (USP)Drug

    0.625 mg/day QID for 3 years

  • Medroxyprogesterone 17-AcetateDrug

    2.5 mg/day QID for 3 years

  • PlaceboDrug

    2 pills/day QID for 3 years

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. HDL subpopulation distribution and compositionTime frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • HNRCA at Tufts University

    Boston, Massachusetts

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.